Kusajili – Clinical trials directory

Result of your search per sponsor: PIERRE FABRE MEDICAMENT (Represented by: Institut de Recherche Pierre Fabre)

Woman and Man Max 99 years
PIERRE FABRE MEDICAMENT (Represented by: Institut de Recherche Pierre Fabre) Update Il y a 4 ans

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides To assess efficacy of V0002 CA 1 g at 3 capsules /day on preventing niacin-induced flushing promoted by Niaspan® administration

Country None
organs None
Specialty None

unknown

More information